This biotech could earn its third new drug approval in as many years.
News & Analysis: Alnylam Pharmaceuticals
The stock is up an amazing 2,100% since the company went public, stomping the S&P 500.
ALNY earnings call for the period ending March 31, 2020.
The impact of the pandemic led the biopharmaceutical company to trim its revenue guidance for polyneuropathy treatment Onpattro.
The partners will develop VIR-2703, which has the potential to prevent COVID-19, and also to treat it.
These development-stage drug companies are well positioned for success, even amid the current market uncertainty.
The multipart deal will, among other things, give the world's largest alternative investment firm a piece of the profits from the biotech's revolutionary new cholesterol drug.
Will a 14-year head start prove to be an advantage between these biotechs?
Three words: Coronavirus market meltdown.
The World Health Organization gave context around its confirmed fatality rate for the rapidly-spreading illness.